We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

HDAC Activity in Peripheral Skeletal Muscle in COPD

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00180752
First Posted: September 16, 2005
Last Update Posted: February 19, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Michael Polkey, Imperial College London
  Purpose
We wish to study the effect of Chronic Obstructive Pulmonary Disease on the activity of the nuclear transcription pathway in peripheral skeletal muscle to determine whether altered activity of this pathway may be responsible for the muscle dysfunction observed in these patients.

Condition
COPD

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Investigation of HDAC and NF Kappa B Activity in Peripheral Skeletal Muscle in COPD

Further study details as provided by Michael Polkey, Imperial College London:

Biospecimen Retention:   Samples With DNA
Plasma and serum samples, quadriceps muscle specimens

Enrollment: 31
Study Start Date: September 2005
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Detailed Description:
Peripheral muscle dysfunction is well recognised in COPD. We wish to study patients who we have found to have weak quadriceps muscles and study the molecular mechanisms underlying this problem. Patients will be well characterised with regard to their physiologic parameters and quadriceps muscle biopsies will be taken. These biopsy samples will be analysed with respect to NFkappaB activity and HDAC activity by nuclear extraction and for muscle inflammatory cytokines. We know that in the lung tissue of COPD patients there is evidence of a reduction in HDAC activity which might be responsible for the higher levels of pronflammatory cytokines in the lung. We will also study a healthy control group and a small selection of patients who are in respiratory failure due to idiopathic scoliosis in the same way.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
COPD patients and healthy age-and sex-matched controls
Criteria

Inclusion Criteria:

COPD

Exclusion Criteria:

Aspirin therapy Bleeding diasthesis Neuromuscular disease

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00180752


Locations
United Kingdom
Royal Brompton Hospital
London, United Kingdom, SW3 6NP
Sponsors and Collaborators
Imperial College London
Investigators
Principal Investigator: Michael I Polkey, PhD Royal Brompton & Harefield NHS Foundation Trust
  More Information

Publications:
Responsible Party: Michael Polkey, Professor of Respiratory Medicine, Imperial College London
ClinicalTrials.gov Identifier: NCT00180752     History of Changes
Other Study ID Numbers: MusHDAC -1
First Submitted: September 13, 2005
First Posted: September 16, 2005
Last Update Posted: February 19, 2016
Last Verified: August 2008
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No